Oncopeptides will present a robust program, including five scientific abstracts featuring new translational and clinical research, alongside a symposium.

"EHA is a cornerstone event for the hematology community, and it is a privilege to welcome our customers, partners and colleagues here in Stockholm," says Sofia Heigis, CEO of Oncopeptides. "Our presence this year reflects our commitment to advancing the science behind PDCs. By bridging the gap between mechanistic discovery and real-world clinical application, we aim to provide clinicians with the tools necessary to navigate the complex, rapidly evolving treatment landscape for patients with multiple myeloma."

For the congress, five abstracts with data that deepen the scientific understanding of the Peptide-Drug Conjugate (PDC) melflufen (Pepaxti) will be presented. The abstracts will also be available in the HemaSphere EHA 2026 abstract book:

• Mechanistic Insights (EHA-5674): New translational data demonstrates that melflufen induces damage to both nuclear and mitochondrial DNA. This dual targeting highlights mitochondrial involvement as a key component of melflufen’s cytotoxic mechanism, potentially allowing it to overcome resistance mediated by cell cycle regulation and traditional DNA repair pathways.
• Predictive Biomarkers (EHA-4492): Findings suggest that melflufen may be particularly effective in patients with an exhausted immune system—a common profile in heavily pretreated multiple myeloma patients. The data identifies potential biomarkers (ERAP2, PSMA3, and USP16) that may help predict melflufen sensitivity, supporting a more tailored approach to patient stratification.
• Real-World use from the Spanish Registry (EHA-3927): The largest report to date on the use of melflufen in patients with relapsed, refractory multiple myeloma (RRMM) in the real-world setting. Data suggest that this regimen is a safe and effective option for these challenging patients, including those previously exposed to immunotherapies.
• Clinical Real-World Evidence (EHA-3027): An update on the LAGOON (OP-115) study, a prospective, non-interventional study in Spain, continues to provide vital real-world data on the effectiveness and safety of melflufen in routine clinical practice.
• Renal Safety Profile (EHA-4509): Further analysis of pooled clinical data reinforces that melflufen maintains stable renal function in RRMM patients, including those with moderate renal impairment, with no signal of increased toxicity.

Parts of the data presented at EHA was also recently presented at the COMy congress in Paris.

In addition to the scientific abstracts, Oncopeptides will host a symposium titled: Beyond immunotherapy - exploring the treatment class of PDCs and clinical realities.

The session, open to congress attendees, will focus on the practical challenges of treatment sequencing in RRMM. As immunotherapy becomes a standard treatment pathway, it often necessitates new strategies for subsequent lines of therapy. Experts will discuss how the unique PDC design of melflufen offers an outpatient-friendly option that does not rely on immune activation or surface antigen targeting.

• Date: Thursday, June 11, 2026
• Time: 10:00–11:30 CEST
• Location: Hall A7, Stockholmsmässan, Stockholm, Sweden

Summary of abstracts published for EHA 2026.

 
For more information, including Questions and Answers for investors, please visit www.oncopeptides.com.